Gland Pharma, a Hyderabad based Pharmaceutical Company, has an Initial Public Offering (IPO) that includes a fresh issue of shares worth up to Rs 1,250 crore and, had filed preliminary papers with markets regulator Sebi.
Along with the IPO of Rs 1,250 crore which comprises of fresh issue of share and an offer for sale of equity shares by promoters up to 3,48,63,635 in which 1,93,68,686 equity shares by Fosun Pharma Industrial Pte Ltd, Gland Celsus Bio Chemicals by 1,00,47,435, up to 35,73,014 equity shares by Empower Discretionary Trust, and Nilay Discretionary Trust by 18,74,500 shares.
Gland Pharma in its seven manufacturing facilities, four at Hyderabad and three at Visakhapatnam, with 3,791 people in India. Developing, manufacturing and markets complex injectables with an established portfolio of products in various therapeutic segments such as anti-infectives, antineoplastics, anti-diabetic, anti-malaria, cardiac, gastrointestinal, blood-related and a combination of delivery systems in hormones including lyophilized vials, liquid vials, ampoules, pre-filled syringes, bangs and drops. The company sells its products under a business-to-business model in over 60 countries.
It would be India’s first company with Chinese parent to list on bourses if the issue gets through successfully. Fosun Pharma acquired 74 per cent stake in the company in 2017 and thus, backed by China’s Fosun Pharma. Gland Pharma has also reported a 71 per cent growth in FY20 profit at Rs 772.85 crore and 28.8 per cent rise in revenue at Rs 2,633.24 crore against the previous year.

Read EquityPandit’s Nifty Outlook for the Week